- Home
- YQ vs VTGN Comparison
YQ vs VTGN Comparison
Compare YQ & VTGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | YQ | VTGN |
|---|---|---|
| Founded | 2012 | 1998 |
| Country | China | United States |
| Employees | 340 | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.7M | 21.8M |
| IPO Year | 2020 | 2014 |
Fundamental Metrics
Financial Performance| Metric | YQ | VTGN |
|---|---|---|
| Price | $2.52 | $0.60 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $0.90 |
| AVG Volume (30 Days) | 3.1K | ★ 548.8K |
| Earning Date | 03-24-2026 | 02-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ N/A | N/A |
| Revenue This Year | N/A | $124.49 |
| Revenue Next Year | N/A | $353.99 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.26 | $0.43 |
| 52 Week High | $6.45 | $5.14 |
Technical Indicators
Market Signals| Indicator | YQ | VTGN |
|---|---|---|
| Relative Strength Index (RSI) | 32.88 | 45.14 |
| Support Level | $2.44 | $0.57 |
| Resistance Level | $3.74 | $0.65 |
| Average True Range (ATR) | 0.14 | 0.04 |
| MACD | -0.03 | 0.01 |
| Stochastic Oscillator | 9.62 | 31.53 |
Price Performance
Historical ComparisonAbout YQ 17 Education & Technology Group Inc.
17 Education & Technology Group Inc is an education technology company in China. It offers smart, in-school, teaching and learning SaaS offerings assist students, teachers, schoolmasters and educational authorities across China. It also offer other educational products and services that complement students' in-school learning. Geographically group operates in China.
About VTGN VistaGen Therapeutics Inc.
Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.